Scilex Holding (NASDAQ:SCLX) Stock, Quote.Headers.trade-ideas

Scilex Holding

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Wall Street

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

MURA

PDYN

SCLX

SGMT

VITL

This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Men,,Tablet,And,Barista,With,Pride,,Small,Business,And,Colleagues

Equities

Macro Economic Events

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Small Business

Tech

ETFs

CRDF

CRVO

GOEV

NRDY

UNFI

Small businesses are entering the holiday season with newfound confidence and momentum, thanks to post-election policies and reduced inflation.

US Small Business Optimism Hits 3-Year High As Election Results &#39;Signal A Major Shift&#39;

Press Releases

DECA

Semnur Pharmaceuticals, Inc., A Wholly Owned Subsidiary Of Scilex Holding Company, Announces Today The Filing Of A Registration Statement On Form S-4 by Denali Capital Acquisition Corp. With The Securities And Exchange Commission Relating To The Previously Announced Proposed Business Combination Between Semnur And Denali

Scilex Holding Co

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.
78% of subjects maintained a clinically meaningful benefit of more than 3 points in rVCSS at 24 months, with an average improvement of 8.2 points among the responder cohort.
Subjects continued to experience a median 75% reduction in pain at 24 months.
Interim follow-up data indicate sustained improvements across all venous specific quality-of-life(QoL) indicators.
PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the second half of 2025.
IRVINE, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / February 7, 2025 / enVVeno Medical Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced that interim two-year follow-up data on 34 subjects from the VenoValve U.S. pivotal trial will be presented today by Dr. Matthew Smeds, Professor of Surgery in the Division of Vascular and Endovascular Surgery at Saint Louis University and Principal Investigator for the trial, at the <a href="https://pr.report/6xb2">Vascular and Endovascular Surgery Society (VESS) 2025 Annual Winter Meeting</a>, being held February 6-9, 2025 in Breckenridge, CO. The Company has submitted a pre-market authorization (PMA) application for the VenoValve to the U.S. Food and Drug Administration (FDA), and the review process is ongoing, with a decision anticipated in the second half of 2025.
Key interim two-year follow-up data being presented at VESS includes:
78% of subjects (n=25/32) maintained a clinically meaningful benefit, defined as an improvement of 3 or more points in the revised Venous Clinical Severity Score (rVCSS).
Among the responder cohort, the average rVCSS improvement increased from 6.6 points at 12 months to 8.2 points at 24 months, demonstrating increasing benefit over time.
At 24 months, subjects continued to experience a median 75% reduction in pain, as measured by the Visual Analog Scale (VAS).
Patient-reported outcomes also demonstrated sustained improvements across all venous specific QoL indicators (VEINES-QoL/Sym) from 12 months to 24 months.
Among the subjects with core lab-evaluable data at 24 months, a 100% device patency rate was observed in all 27 subjects.
The rVCSS is a clinically validated scoring system used to track the progression or regression of venous diseases. The FDA previously indicated that an improvement of 3 or more points in rVCSS would be evidence of the VenoValve's clinical benefit.

Biotech

General

NVNO

enVVeno Medical Announces Hancock Jaffe's VenoValve Trial Shows 75% Pain Reduction at 24 Months; 78% Of Patients Maintain Over 3-Point Improvement In rVCSS At 24 Months; FDA Decision Anticipated In H2 2025

WIIM

Graham shares are trading lower after the company reported worse-than-expected Q3 revenue results.

SRAD

Sportradar shares are trading higher after the company announced a long-term partnership extension with Major League Baseball, which includes MLB acquiring an equity stake in the company.

Pagaya Technologies shares are trading higher after Citigroup upgraded the stock from Neutral to Buy and raised its price target from $13 to $14.5.

<a href="https://www.sec.gov/Archives/edgar/data/1796022/000119312525022317/d919091ds3asr.htm" title="https://www.sec.gov/Archives/edgar/data/1796022/000119312525022317/d919091ds3asr.htm">https://www.sec.gov/Archives/edgar/data/1796022/000119312525022317/d919091ds3asr.htm</a>

Offerings

STEP

StepSpstone Group Files For Mixed Shelf; Size Not Disclosed

Sports

MLB Has Acquired Equity Stake In Sportradar; Under New Terms, Sportradar Will Exclusively Distribute MLB's Ultra-Low Latency Official Data, Media Content And AV Content

LESL

Leslie's shares are trading lower after Telsey Advisory Group cut its price target on the stock from $3.75 to $3.0

AZPN

Elliott Investment Management L.P. Which Manages Funds In Aspen Technolog Issued The Following Statement Regarding The Com's Recently Announced Agreement With Emerson Electric Co. ""As The Largest Minority Investor In Aspentech, We Disagree With The Company's Decision To Support A $265.00 Per Share Tender Offer By Its Majority Stockholder, Emerson, To Acquire The Aspentech Shares It Does Not Already Own...."

Media

MLB And Sportradar Extend Exclusive Partnership Through 2032

McEwen shares are trading lower after the company announced a $95 million convertible senior offering via private placement.

Federal Reserve

Fed's Kashkari Says If We See Good Inflation Data And Labor Market Stays Strong, That Would Move Me To Supporting Further Rate Cut

DA Davidson analyst Linda Bolton Weiser downgrades e.l.f. Beauty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELF#NYSE">ELF</a>) from Buy to Neutral and lowers the price target from $170 to $80.

Downgrades

Price Target

DA Davidson Downgrades e.l.f. Beauty to Neutral, Lowers Price Target to $80

FED's Kashkari: Says We Are in a Good Place To Sit Here Until We Get More Information On Administration's Policies; Asked About Tariff Policy, 'We Need to Wait and See'

Across the recent three months, 12 analysts have shared their insights on Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), expressing a variety of opinions spanning from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Doximity, presenting an average target of $58.33, a high estimate of $82.00, and a low estimate of $43.00. Surpassing the previous average price target of $46.67, the current average has increased by 24.98%.
<img src="https://www.benzinga.com/files/images/story/2025/1738936849_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Doximity by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scott Berg</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$82.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$43.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Steven Valiquette</td>
<td>Mizuho</td>
<td>Announces</td>
<td>Neutral</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$48.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Roman</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$58.00</td>
<td>-</td>
</tr>
<tr>
<td>Jailendra Singh</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$49.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Ricky Goldwasser</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$53.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Richard Close</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$60.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$75.00</td>
<td>$52.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Doximity. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Doximity compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Doximity's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Doximity's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DOCS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Doximity analyst ratings.</a>
<h2>Discovering Doximity: A Closer Look</h2>
Doximity Inc is a digital platform for U.S. medical professionals. Its cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers.
<h3>Key Indicators: Doximity's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Doximity showcased positive performance, achieving a revenue growth rate of 20.44% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Doximity's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 32.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Doximity's ROE excels beyond industry benchmarks, reaching 4.71%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 4.03%, the company showcases effective utilization of assets.
Debt Management: Doximity's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DOCS

Deep Dive Into Doximity Stock: Analyst Perspectives (12 Ratings)

Throughout the last three months, 11 analysts have evaluated DraftKings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>), offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for DraftKings, presenting an average target of $52.73, a high estimate of $60.00, and a low estimate of $44.00. Marking an increase of 1.76%, the current average surpasses the previous average price target of $51.82. 
<img src="https://www.benzinga.com/files/images/story/2025/1738936830_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of DraftKings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Lance Vitanza</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Stauff</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$54.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Joseph Greff</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$53.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Stephen Glagola</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Chad Beynon</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brandt Montour</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$52.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to DraftKings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DraftKings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of DraftKings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DKNG/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DraftKings analyst ratings.</a>
<h2>Discovering DraftKings: A Closer Look</h2>
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number two or three revenue share position across states in which it competes. DraftKings is now live with online or retail sports betting in about 30 states and iGaming in seven states, with both products available to around 40% of Canada's population. The company also operates a non-fungible token commissioned-based marketplace and develops and licenses online gaming products.
<h3>DraftKings's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Positive Revenue Trend: Examining DraftKings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 38.68% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: DraftKings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -26.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DraftKings's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -24.74%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): DraftKings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.92%, the company may face hurdles in achieving optimal financial returns.
Debt Management: DraftKings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.25.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DKNG

Where DraftKings Stands With Analysts

Marvell Tech's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NYSE">MRVL</a>) short percent of float has risen 3.76% since its last report. The company recently reported that it has 20.25 million shares sold short, which is 2.76% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.98 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Marvell Tech Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738936826_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Marvell Tech has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Marvell Tech's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Marvell Tech's peer group average for short interest as a percentage of float is 5.38%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

MRVL

Peering Into Marvell Tech's Recent Short Interest

TAL Education's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) short percent of float has risen 22.17% since its last report. The company recently reported that it has 40.16 million shares sold short, which is 10.03% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.95 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>TAL Education Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738936820_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for TAL Education has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing TAL Education's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, TAL Education's peer group average for short interest as a percentage of float is 4.37%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(TAL) - Analyzing TAL Education's Short Interest

Across the recent three months, 10 analysts have shared their insights on Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.1, a high estimate of $17.00, and a low estimate of $6.00. Surpassing the previous average price target of $9.63, the current average has increased by 4.88%.
<img src="https://www.benzinga.com/files/images/story/2025/1738936818_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive Sprinklr is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Pinjalim Bora</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$8.50</td>
<td>$7.70</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Parker Lane</td>
<td>Stifel</td>
<td>Raises</td>
<td>Hold</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brett Knoblauch</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.50</td>
<td>$10.50</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sprinklr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sprinklr compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sprinklr's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CXM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sprinklr analyst ratings.</a>
<h2>Unveiling the Story Behind Sprinklr</h2>
Sprinklr Inc is engaged in providing enterprise software that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, and communicate across digital channels. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in Americas, EMEA and other countries. It derives maximum revenue from Americas.
<h3>Sprinklr: A Financial Overview</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Sprinklr displayed positive results in 3 months. As of 31 October, 2024, the company achieved a solid revenue growth rate of approximately 7.71%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Sprinklr's net margin excels beyond industry benchmarks, reaching 5.21%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sprinklr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.16%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Sprinklr's ROA excels beyond industry benchmarks, reaching 1.07%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Sprinklr: Insights From 10 Analyst Reviews

Morningstar's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NYSE">MORN</a>) short percent of float has risen 8.12% since its last report. The company recently reported that it has 569 thousand shares sold short, which is 2.13% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.04 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Morningstar Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738936815_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Morningstar has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Morningstar's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Morningstar's peer group average for short interest as a percentage of float is 3.20%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

MORN

Looking Into Morningstar's Recent Short Interest

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 5 years by 3.2% on an annualized basis producing an average annual return of 15.78%. Currently, Morningstar has a market capitalization of $14.03 billion. 
Buying $1000 In MORN: If an investor had bought $1000 of MORN stock 5 years ago, it would be worth $2,072.03 today based on a price of $327.07 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738936810_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Morningstar 5 Years Ago Would Be Worth This Much Today

Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination

Health Care

Scilex Holding Company Announces Pain Medicine News Published Retrospective Claims Data on ZTlido® vs. Lidocaine 5% Patch

Scilex Holding Company Amends its License Agreement with Romeg Therapeutics, LLC, For the Worldwide Rights to Commercialize Gloperba®, an FDA-Approved Prophylactic Treatment for Painful Gout Flares in Adults

Scilex Holding Company Announces Filing of its Quarterly Report on Form 10-Q for the Quarter Ended September 30, 2024

Scilex Holding Company Announces that It Will Be Filing Today of a Supplemental New Drug Application with the FDA for ELYXYB® in Acute Pain Indication

Scilex Holding Company Announces that Its Note Holders Intend to Participate in the Funding and Licensing of Gloperba® Ex-U.S. Commercialization Rights from Romeg Therapeutics, LLC

Contracts

Scilex Holding Company Announces Extension of the Maturity Date of its Secured Promissory Note Issued to Oramed Pharmaceuticals Inc. to December 31, 2025

Scilex Holding Company Announces that It Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)

Scilex Holding Company Announces that the U.S. FDA Has Acknowledged the Submission of Our Supplemental New Drug Application for ELYXYB® in Acute Pain Indication

Dividends

Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Dividend Stock Previously Distributed by Sorrento to its Stockholders as a Dividend to April 14, 2025

SRNE

ALT5 Sigma

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

Assertio Holdings

CalciMedica

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Cadrenal Therapeutics, Inc. - Common Stock

Cadrenal Therapeutics

Journey Medical Corporation - Common Stock

Journey Medical

Grace Therapeutics

Ikena Oncology

Opus Genetics

Iterum Therapeutics

NRX Pharmaceuticals

Nutriband

OptiNose

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Rani Therapeutics Holdings, Inc. - Class A Common Stock

Rani Therapeutics Hldgs

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

SCYNEXIS

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals

VYNE Therapeutics

D. Boral Capital

HC Wainwright & Co.

Alliance Global Partners

Rodman & Renshaw

B. Riley Securities

Skyscrapers,Cityscape,Downtown,View,,Nashville,Skyline,Buildings.,Beautiful,Real,Estate.

Scilex Holding Company Announces Signing Of A $50 Million Registered Convertible Financing To Refinance And Restructure Existing Debt &amp; Further Strengthens Financial Profile

United,States,Bankruptcy,Court,Sign

SRNEQ

Scilex Holding Company Announces That The U.S. Bankruptcy Court Has Extended The Lockup Period On Shares Of Scilex Dividend Stock Previously Distributed By Sorrento To Its Stockholders As A Dividend To January 31, 2025

Business,Analyst,Checking,In,Financial,Statement,For,Audit,Internal,Control

Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for the Month Ended July 31, 2024

Hand,Of,Human,Holding,Crystal,Globe,Ball,With,Tree,For

Scilex Holding Company Announces Publication of Its Inaugural Sustainability Report

Business,Man,Sign,A,Contract,Investment,Professional,Document,Agreement.,Meeting

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Businessmen,Making,Handshake,With,Partner,,Greeting,,Dealing,,Merger,And,Acquisition,

Scilex Holding Company Partners With New National Distributor, Endeavor Distribution LLC.

Muscular,Man,Suffering,From,Back,And,Neck,Pain.,Incorrect,Sitting

Scilex Holding Company Announces Publication In PAIN Journal Regarding Phase 3 Results Of The Pivotal Registration Trial Of SP-102 (SEMDEXA™) In Lumbosacral Radicular Pain (Sciatica)

Outside,Of,Logistics,Warehouse,With,Open,Door,,Delivery,Van,Loaded

Scilex Holding Company Announces That Many National Pharmacy Chains And Independent Pharmacies Have Begun Stocking GLOPERBA®

Interior,Of,A,Modern,Warehouse,Storage,Of,Retail,Shop,With

Scilex Holding Company Announces Stocking Of GLOPERBA® Is Underway In All Of The Wholesalers With Which Scilex Has Stocking Arrangements Throughout The U.S.

Comments

Scilex Holding

Scilex Holding (SCLX) Forecast

Scilex Holding (NASDAQ:SCLX) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga